Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB · Entity 5650 | See Remarks | October 06, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,083,848 |
Ending reported balance
After 2026-10-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-06 · Exercise / conversion · Acquired 500,000 · Balance 1,745,663 Row 2 · 2026-10-06 · Sale · Disposed 661,815 · Balance 1,083,848 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. F2: This sale price represents the weighted average sale price of the shares sold ranging from $3.00 to $3.33 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2035-03-31 | Direct | 1,500,000 |
Reported balance
After 2026-10-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-06 · Exercise / conversion · Disposed 500,000 · Balance 1,500,000 F3: 1/4th of the shares subject to the option vested on the one year anniversary of the date of grant, and the balance of shares vest monthly thereafter over the next three years, provided that the Reporting Person continues to serve through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026.
F2: This sale price represents the weighted average sale price of the shares sold ranging from $3.00 to $3.33 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F3: 1/4th of the shares subject to the option vested on the one year anniversary of the date of grant, and the balance of shares vest monthly thereafter over the next three years, provided that the Reporting Person continues to serve through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 8, 2026 20:07 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001384133-26-000004 · wk-form4_1791490061.xml · derivative · entry 3 Gibson James R II · CIK 0001384133 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 500,000 shares Expires 2035-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to the option vested on the one year anniversary of the date of grant, and the balance of shares vest monthly thereafter over the next three years, provided that the Reporting Person continues to serve through each vesting date. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 20:07 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 661,815 | $3.11 | $2,056,921.02 |
DisclosureSEC source: 0001384133-26-000004 · wk-form4_1791490061.xml · nonDerivative · entry 2 Gibson James R II · CIK 0001384133 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,083,848 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $3.00 to $3.33 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 20:07 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionCommon Stock | 500,000 | $1.18 | $590,000.00 |
DisclosureSEC source: 0001384133-26-000004 · wk-form4_1791490061.xml · nonDerivative · entry 1 Gibson James R II · CIK 0001384133 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,745,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:05 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 88,185 | $1.37 | $120,813.45 |
DisclosureSEC source: 0001299130-26-000054 · wk-form4_1775246701.xml · nonDerivative · entry 1 Gibson James R II · CIK 0001384133 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,245,663 F1 · shares: Represents the number of shares mandatorily sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $1.35 to $1.39 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:14 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 667,696 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001299130-26-000039 · wk-form4_1772579681.xml · derivative · entry 2 Gibson James R II · CIK 0001384133 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667,696 Underlying: Common Stock · 667,696 shares Expires 2036-02-27 F2 · derivative.exercise_date: The shares subject to the option will vest in 36 equal monthly installments beginning on March 27, 2026, subject to the Reporting Person's continued status as a service provider through the applicable vesting dates. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:14 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantCommon Stock | 333,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001299130-26-000039 · wk-form4_1772579681.xml · nonDerivative · entry 1 Gibson James R II · CIK 0001384133 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,333,848 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on February 15 of each of 2027, 2028, and 2029, subject to the Reporting Person's continued status as a service provider through the applicable vesting dates. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:18 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 2,000,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001299130-25-000079 · wk-form4_1743625109.xml · derivative · entry 2 Gibson James R II · CIK 0001384133 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2035-03-31 F2 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on the one year anniversary of the date of grant, and the balance of shares will vest monthly thereafter over the next three years, provided that the Reporting Person continues to serve through each vesting date. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:18 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001299130-25-000079 · wk-form4_1743625109.xml · nonDerivative · entry 1 Gibson James R II · CIK 0001384133 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on March 31 of each of 2026, 2027, 2028 and 2029, provided that the Reporting Person continues to serve through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.